Targeting inhibitor of apoptosis proteins (IAPs) with IAP inhibitors sensitises malignant rhabdoid tumour cells to cisplatin. (2022)

• Record Type: Journal Article
• Authors: Coyle, Rachel; O'Sullivan, Maureen J; Zisterer, Daniela M
• Is Part Of: Cancer treatment and research communications. Number 32(2022)
• Publication Date: 2022
• Subjects: Malignant rhabdoid tumour -- Inhibitor of Apoptosis Proteins -- Cisplatin -- BV6 -- XIAP
• DOI: 10.1016/j.ctarc.2022.100579
• Languages: English
• ISSNs: 2468-2942

Abstract

Highlights: The SMAC mimetic BV6 synergistically enhances cisplatin-mediated apoptosis of MRT cells The XIAP inhibitor embelin also sensitises MRT cells to cisplatin Expression of XIAP, its target caspase 3, and its inhibitor SMAC in MRT patient samples Pre-clinical promise for IAP-targeting therapeutic approach for MRT Abstract: Malignant rhabdoid tumour (MRT) is a rare, aggressive paediatric malignancy most commonly diagnosed in those below the age of three. MRTs can arise in soft tissue but are more often associated with the central nervous system or kidney. Unfortunately, the prognosis upon diagnosis with MRT is poor. Given the resistance of MRT to current treatment protocols including cisplatin, and the vulnerability of this young patient population to aggressive therapies, there is a need for novel treatment options. Several members of the inhibitor of apoptosis protein (IAP) family including X‑linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/cIAP2), livin and survivin have been implicated in chemotherapy resistance in various malignancies. We have previously demonstrated expression of these IAP family members in a panel of MRT cell lines. In the present study, sensitivity of this same panel of MRT cell lines to small-molecule mediated inhibition of the IAPs via the survivin inhibitor YM155 and the XIAP/cIAP1/cIAP2 inhibitor BV6 was demonstrated. Additionally, both BV6 and the XIAP inhibitor embelin synergistically enhanced cisplatin mediated apoptotic cell death in MRT cell lines, with enhanced caspase-3 cleavage. Importantly, we have demonstrated, for the first time, expression of XIAP, its target caspase-3 and its endogenous inhibitor SMAC in rhabdoid tumour patient tissue. In conclusion, this study provides pre-clinical evidence that IAP inhibition may be a new therapeutic option in MRT.